Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Upgraded by StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

PBH has been the topic of several other reports. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $74.67 on Tuesday. Prestige Consumer Healthcare has a fifty-two week low of $58.18 and a fifty-two week high of $86.36. The company has a market cap of $3.69 billion, a PE ratio of 18.17, a P/E/G ratio of 2.32 and a beta of 0.51. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The business has a 50-day simple moving average of $80.50 and a two-hundred day simple moving average of $74.07.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period last year, the business earned $1.07 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down .9% on a year-over-year basis. As a group, equities analysts expect that Prestige Consumer Healthcare will post 4.44 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares of the company’s stock, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 38,810 shares of company stock worth $3,187,300 over the last quarter. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in PBH. Martingale Asset Management L P grew its stake in Prestige Consumer Healthcare by 0.4% in the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock valued at $2,666,000 after acquiring an additional 140 shares during the period. Horizon Kinetics Asset Management LLC grew its position in shares of Prestige Consumer Healthcare by 4.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock valued at $234,000 after purchasing an additional 150 shares during the period. Evergreen Capital Management LLC grew its position in shares of Prestige Consumer Healthcare by 5.4% in the second quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock valued at $216,000 after purchasing an additional 160 shares during the period. OLD National Bancorp IN increased its stake in shares of Prestige Consumer Healthcare by 4.4% during the third quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock worth $287,000 after purchasing an additional 168 shares in the last quarter. Finally, Huntington National Bank raised its position in shares of Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.